Galapagos NV - American Depositary Shares (GLPG)
23.52
+0.48 (2.08%)
NASDAQ · Last Trade: Apr 8th, 8:02 PM EDT
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...
Via Newsfile · May 30, 2024

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers
By Frontier Medicines · Via GlobeNewswire · February 22, 2024